Business
Mustang Bio to Participate in Three January 2021 Virtual Investor Conferences
WORCESTER, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on
About this update from Mustang Bio, Inc.
[{"type":"text","content":"WORCESTER, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in three virtual investor conferences in January 2021. Details of the events are as follows: 10th Annual LifeSci Partners Corporate Access Event: The company will host virtual one-on-one meetings during the conference on Wednesday, January 6 through Friday, January 8 and Monday, January 11 through Thursday, January 14, 2021.H.C. Wainwright Virtual BioConnect Conference: The company’s presentation will be available for on-demand viewing on Mustang’s website beginning Monday, January 11, 2021, at 6:00 a.m. EST.B. Riley Securities’ Virtual Oncology Investor Conference: The company’s presentation will take place on Thursday, January 21, 2021, at 1:30 p.m. EST and will be available to all conference-registered institutional investors. Webcasts of the H.C. Wainwright and B. Riley presentations will be available on the Events page of the Investors Relations section of Mustang’s website, www.mustangbio.com, for approximately 30 days following each presentation. About Mustang BioMustang Bio, Inc. (“Mustang”) is a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market. Mustang has partnered with top medical institutions to advance the development of CAR T therapies across multiple cancers, as well as a lentiviral gene therapy for XSCID. Mustang is registered under the Securities Exchange Act of 1934, as amended, and files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). Mustang was founded by Fortress Biotech, Inc. (NASDAQ: FBIO). For more information, visit www.mustangbio.com. Forward‐Looking StatementsThis press release may contain “forward-looking statements” within...